Key Drivers
- Strong Cash Flow
- Rising Leverage
- Thin Margins
AIAI Summary
Humana is a margin-recovery turnaround—not a membership-growth story—where shedding ~600,000 unprofitable Medicare Advantage members could restore earnings power, but elevated utilization, regulatory risk, and rising leverage leave little room for execution missteps; investors should wait for sustained medical-cost and margin improvement before underwriting the stock's premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Rising Leverage
- •Thin Margins
Hum's stronger quarterly cash flow and earnings are offset by rising leverage, tighter liquidity, thin margins, and a materially richer valuation, warranting cautious monitoring.
Price Behavior
Key Price Behavior Insights:
- •Pullback intensifies
- •$400 pivotal
- •Support tested
HUM's last-month uptrend is weakening after a sharp pullback to $386.22, with recovery above $400 needed to improve momentum and a break below $384 signaling downside risk.
Sharp rebound from near $379 to $410 was largely erased by the
Sentiment & News
Key News Insights:
- •Institutional Accumulation
- •Cost Pressures
- •Leadership Update
Humana saw strong institutional buying and improving sentiment, though elevated costs, debt concerns, and some stake trimming remain key risks.
The buying activity and operational catalysts may support shares, but margin and leverage risks could limit upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings